Seeking Alpha

Allergan loses patent appeal

  • The U.S. Court of Appeals in Washington finds that two of Allergan''s (AGN) patents covering its eyelash drug Latisse are invalid. The patents cover ways to apply the drug to promote eyelash growth.
  • Latisse is a variation of the company's glaucoma drug Lumigan. The company developed it after researchers noted that eyelash growth was a side effect of glaucoma treatments.
  • The court threw out an order preventing Novartis' (NVS) Sandoz, Actavis (ACT) and Apotex from selling generic versions.
  • Allergan expects Latisse to generate ~$110M is sales this year.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector